Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AAV Gene Therapy
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Kriya Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to advance Kriya’s portfolio of gene therapies designed to block complement C3 and C5 for retinal diseases using Everads' suprachoroidal delivery device.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 27, 2023
Lead Product(s) : AAV Gene Therapy
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Kriya Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery
Recipient : VivaVision
Deal Size : Undisclosed
Deal Type : Collaboration
VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases
Details : Under the terms of collaboration agreement, VivaVision and Everads will jointly conduct pre-clinical research activities, in order to identify lead candidates for future clinical development and commercialization.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery
Recipient : VivaVision
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Gene Therapy
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the deal in which the gene therapy company was given a right to negotiate a worldwide license related to specific retinal targets, the companies will explore the feasibility of using Everads' technology to deliver proprietary viral vectors to the c...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : Gene Therapy
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?